# Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

> **NCT00002721** · PHASE1 · COMPLETED · sponsor: **University of New Mexico** · enrollment: 18 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** doxorubicin hydrochloride
- **DRUG:** estramustine phosphate sodium
- **PROCEDURE:** drug resistance inhibition treatment

## Key facts

- **NCT ID:** NCT00002721
- **Lead sponsor:** University of New Mexico
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-03
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002721, "Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00002721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*